Original study (notice n° 516402)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01141cam a2200181 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121093630.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Philippe-Janon, Boris |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Original study |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 44 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The misuse and addictive potential of pregabalin (PGB) were detected about ten years ago. In France, more and more reports from substance abuse services testify to its abuse, especially in the context of multiple substance abuse. This article, based on an assessment of the prevalence of PGB use among patients newly admitted to an Outpatient Addiction Treatment Center (CSAPA) in Lyon, attempts to provide improved guidelines for primary care practice concerning initial prescription, prevention of misuse, the danger of combining these drugs with synthetic opioids, and the prescription of naloxone kits. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Charles, Rodolphe |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Berger-Vergiat, Aurélie |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Médecine | 18 | 4 | 2022-04-01 | p. 156-159 | 1777-2044 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-medecine-2022-4-page-156?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-medecine-2022-4-page-156?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux